Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Proteomics International Laboratories Ltd. ( (AU:PIQ) ).
Proteomics International Laboratories Ltd has applied to the ASX for quotation of 1,164,320 new ordinary fully paid shares, to be issued on 21 January 2026 under its ticker PIQ. The additional securities, arising from the exercise or conversion of existing instruments, modestly expand the company’s quoted capital base, potentially enhancing liquidity for shareholders and supporting ongoing corporate and operational funding needs.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.74 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is an Australian life sciences company focused on proteomics-based diagnostics and analytical services, listed on the ASX under the code PIQ. The company develops and commercialises protein-based tests and technologies aimed at improving disease detection and management in healthcare markets.
Average Trading Volume: 453,346
Technical Sentiment Signal: Buy
Current Market Cap: A$131.2M
Find detailed analytics on PIQ stock on TipRanks’ Stock Analysis page.